Breli Bonheur Ngouama, Jean Claude Djontu, Darrel Ornelle Elion Assiana, Freisnel Hermeland Mouzinga, Mita Naomie Merveille Dello, Jabar Babatunde Pacome Agbo Achimi Abdul, Christopher Mebiame Biyogho, Rhett Chester Mevyann, Guy Arnault Rogue Mfoumbi Ibinda, Micheska Epola Dibamba Ndanga, Franck Hardain Okemba Okombi, Michel Illoye Ayet, Lemercier Khunell Siele, Roélie Foxie Mizele Kitoti, Jeannhey Christevy Vouvoungui, Alain Maxime Mouanga, Alain Brice Vouidibio Mbozo, Veronique Penlap, Ayola Akim Adegnika, Martin Peter Grobusch, Timothy D McHugh, Ali Zumla, Francine Ntoumi
{"title":"在刚果共和国布拉柴维尔抗结核中心就诊的患者的耐药结核病概况。","authors":"Breli Bonheur Ngouama, Jean Claude Djontu, Darrel Ornelle Elion Assiana, Freisnel Hermeland Mouzinga, Mita Naomie Merveille Dello, Jabar Babatunde Pacome Agbo Achimi Abdul, Christopher Mebiame Biyogho, Rhett Chester Mevyann, Guy Arnault Rogue Mfoumbi Ibinda, Micheska Epola Dibamba Ndanga, Franck Hardain Okemba Okombi, Michel Illoye Ayet, Lemercier Khunell Siele, Roélie Foxie Mizele Kitoti, Jeannhey Christevy Vouvoungui, Alain Maxime Mouanga, Alain Brice Vouidibio Mbozo, Veronique Penlap, Ayola Akim Adegnika, Martin Peter Grobusch, Timothy D McHugh, Ali Zumla, Francine Ntoumi","doi":"10.1186/s12941-025-00786-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>WHO strategy to end Tuberculosis (TB) calls for drug susceptibility testing of Mycobacterium tuberculosis (MTB) for all patients, in high TB burden settings. Thus, this study aimed to investigate the MTB drug resistance profiles and related risk factors among patients presenting to the Antituberculosis Center of Brazzaville, Republic of Congo.</p><p><strong>Methods: </strong>A cross-sectional study was carried out from July 2022 to August 2023 involving 1,121 presumptive pulmonary tuberculosis patients enrolled to the Antituberculosis Center of Brazzaville. Sputum samples were collected from all the study participants for the diagnosis of tuberculosis and rifampicin resistance, using the Xpert MTB/RIF (Cepheid, USA) assay. Samples positive for MTB with drug resistance to RIF were further tested for the second line anti-MTB drug susceptibility using the 10-color Xpert MTB/XDR assay.</p><p><strong>Result: </strong>Out of 1,121 presumptive TB patients tested, 302/1,121 (26.9%) were MTB positive. Among these, 18/302 (6.0%) had received previous TB treatment and 15/302 (5.0%) were HIV co-infected. The mean age of the study population was 34 years, with a higher prevalence in males (69.2%). Of the MTB isolates, 25/302 (8.3%) were Rifampicin-resistant, with 24/25 (96%) further confirmed as multi-resistant strains, including 6/24 (25%) pre-XDR. Risk factors for MDR-TB included a history of TB treatment (AOR = 8.96, p = 0.002) and chronic cough (AOR = 7.14, p = 0.003).</p><p><strong>Conclusions: </strong>This study reveals a high level of drug-resistant tuberculosis in Brazzaville, with previous TB treatment being a significant risk factor. The findings underscore the need to strengthen molecular surveillance and TB management and control measures in the Republic of Congo.</p>","PeriodicalId":8052,"journal":{"name":"Annals of Clinical Microbiology and Antimicrobials","volume":"24 1","pages":"31"},"PeriodicalIF":4.6000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065265/pdf/","citationCount":"0","resultStr":"{\"title\":\"Drug-resistant tuberculosis profiles among patients presenting at the antituberculosis center of Brazzaville, Republic of Congo.\",\"authors\":\"Breli Bonheur Ngouama, Jean Claude Djontu, Darrel Ornelle Elion Assiana, Freisnel Hermeland Mouzinga, Mita Naomie Merveille Dello, Jabar Babatunde Pacome Agbo Achimi Abdul, Christopher Mebiame Biyogho, Rhett Chester Mevyann, Guy Arnault Rogue Mfoumbi Ibinda, Micheska Epola Dibamba Ndanga, Franck Hardain Okemba Okombi, Michel Illoye Ayet, Lemercier Khunell Siele, Roélie Foxie Mizele Kitoti, Jeannhey Christevy Vouvoungui, Alain Maxime Mouanga, Alain Brice Vouidibio Mbozo, Veronique Penlap, Ayola Akim Adegnika, Martin Peter Grobusch, Timothy D McHugh, Ali Zumla, Francine Ntoumi\",\"doi\":\"10.1186/s12941-025-00786-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>WHO strategy to end Tuberculosis (TB) calls for drug susceptibility testing of Mycobacterium tuberculosis (MTB) for all patients, in high TB burden settings. Thus, this study aimed to investigate the MTB drug resistance profiles and related risk factors among patients presenting to the Antituberculosis Center of Brazzaville, Republic of Congo.</p><p><strong>Methods: </strong>A cross-sectional study was carried out from July 2022 to August 2023 involving 1,121 presumptive pulmonary tuberculosis patients enrolled to the Antituberculosis Center of Brazzaville. Sputum samples were collected from all the study participants for the diagnosis of tuberculosis and rifampicin resistance, using the Xpert MTB/RIF (Cepheid, USA) assay. Samples positive for MTB with drug resistance to RIF were further tested for the second line anti-MTB drug susceptibility using the 10-color Xpert MTB/XDR assay.</p><p><strong>Result: </strong>Out of 1,121 presumptive TB patients tested, 302/1,121 (26.9%) were MTB positive. Among these, 18/302 (6.0%) had received previous TB treatment and 15/302 (5.0%) were HIV co-infected. The mean age of the study population was 34 years, with a higher prevalence in males (69.2%). Of the MTB isolates, 25/302 (8.3%) were Rifampicin-resistant, with 24/25 (96%) further confirmed as multi-resistant strains, including 6/24 (25%) pre-XDR. Risk factors for MDR-TB included a history of TB treatment (AOR = 8.96, p = 0.002) and chronic cough (AOR = 7.14, p = 0.003).</p><p><strong>Conclusions: </strong>This study reveals a high level of drug-resistant tuberculosis in Brazzaville, with previous TB treatment being a significant risk factor. The findings underscore the need to strengthen molecular surveillance and TB management and control measures in the Republic of Congo.</p>\",\"PeriodicalId\":8052,\"journal\":{\"name\":\"Annals of Clinical Microbiology and Antimicrobials\",\"volume\":\"24 1\",\"pages\":\"31\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065265/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Clinical Microbiology and Antimicrobials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12941-025-00786-8\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical Microbiology and Antimicrobials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12941-025-00786-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：世卫组织终止结核病战略要求在结核病高负担环境中对所有患者进行结核分枝杆菌（MTB）药敏试验。因此，本研究旨在调查在刚果共和国布拉柴维尔抗结核中心就诊的患者中MTB耐药性概况和相关危险因素。方法：从2022年7月至2023年8月进行横断面研究，纳入布拉柴维尔抗结核中心的1121例疑似肺结核患者。使用Xpert MTB/RIF（美国造父变星）测定法，收集所有研究参与者的痰样本以诊断结核病和利福平耐药性。采用10色Xpert MTB/XDR法进一步检测对RIF耐药的MTB阳性样品的二线抗MTB药物敏感性。结果：1121例推定结核病患者中，302/ 1121（26.9%）为MTB阳性。其中18/302（6.0%）曾接受过结核病治疗，15/302（5.0%）合并感染艾滋病毒。研究人群的平均年龄为34岁，男性患病率较高（69.2%）。在结核分枝杆菌分离株中，25/302株（8.3%）对利福平耐药，24/25株（96%）进一步证实为多重耐药菌株，其中6/24株（25%）为xdr前菌株。耐多药结核病的危险因素包括结核病治疗史（AOR = 8.96, p = 0.002）和慢性咳嗽（AOR = 7.14, p = 0.003）。结论：这项研究揭示了布拉柴维尔耐药结核病的高水平，以前的结核病治疗是一个重要的危险因素。这些发现强调了在刚果共和国加强分子监测和结核病管理与控制措施的必要性。
Drug-resistant tuberculosis profiles among patients presenting at the antituberculosis center of Brazzaville, Republic of Congo.
Background: WHO strategy to end Tuberculosis (TB) calls for drug susceptibility testing of Mycobacterium tuberculosis (MTB) for all patients, in high TB burden settings. Thus, this study aimed to investigate the MTB drug resistance profiles and related risk factors among patients presenting to the Antituberculosis Center of Brazzaville, Republic of Congo.
Methods: A cross-sectional study was carried out from July 2022 to August 2023 involving 1,121 presumptive pulmonary tuberculosis patients enrolled to the Antituberculosis Center of Brazzaville. Sputum samples were collected from all the study participants for the diagnosis of tuberculosis and rifampicin resistance, using the Xpert MTB/RIF (Cepheid, USA) assay. Samples positive for MTB with drug resistance to RIF were further tested for the second line anti-MTB drug susceptibility using the 10-color Xpert MTB/XDR assay.
Result: Out of 1,121 presumptive TB patients tested, 302/1,121 (26.9%) were MTB positive. Among these, 18/302 (6.0%) had received previous TB treatment and 15/302 (5.0%) were HIV co-infected. The mean age of the study population was 34 years, with a higher prevalence in males (69.2%). Of the MTB isolates, 25/302 (8.3%) were Rifampicin-resistant, with 24/25 (96%) further confirmed as multi-resistant strains, including 6/24 (25%) pre-XDR. Risk factors for MDR-TB included a history of TB treatment (AOR = 8.96, p = 0.002) and chronic cough (AOR = 7.14, p = 0.003).
Conclusions: This study reveals a high level of drug-resistant tuberculosis in Brazzaville, with previous TB treatment being a significant risk factor. The findings underscore the need to strengthen molecular surveillance and TB management and control measures in the Republic of Congo.
期刊介绍：
Annals of Clinical Microbiology and Antimicrobials considers good quality, novel and international research of more than regional relevance. Research must include epidemiological and/or clinical information about isolates, and the journal covers the clinical microbiology of bacteria, viruses and fungi, as well as antimicrobial treatment of infectious diseases.
Annals of Clinical Microbiology and Antimicrobials is an open access, peer-reviewed journal focusing on information concerning clinical microbiology, infectious diseases and antimicrobials. The management of infectious disease is dependent on correct diagnosis and appropriate antimicrobial treatment, and with this in mind, the journal aims to improve the communication between laboratory and clinical science in the field of clinical microbiology and antimicrobial treatment. Furthermore, the journal has no restrictions on space or access; this ensures that the journal can reach the widest possible audience.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
